Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 6, 2007, Pages 328-334

  Fauler, Guenter ^a   Abletshauser, C ^b   Erwa, W ^a   Loser R ^c   Witschital, K ^d   Marz W ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Klinikum Starnberg   (Germany)

^c Fujisawa Deutschland   (Germany)

^d BioProof AG   (Germany)

Author keywords

Fluvastatin 80 mg extended release formulation; Mevalonic acid; Morning versus evening closing; Pharmacokinetics of fluvastatin

Indexed keywords

CHOLESTEROL; CREATININE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; OPEN STUDY; PHARMACODYNAMICS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; URINARY EXCRETION;

EID: 34250222092     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45328     Document Type: Article

References (27)

1. American Heart Association. Our Dietary Recommendations (web site available at: www.americanheart.org/presenter.jhtml?identifier-851,) accessed: March 22, 2005
2. Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol. 2000; 86: 759-763.
3. Ballantyne CM, Pazzuchoni F Pinto X, Reckless JP, Stein E, McKenny J, Bortolini M, Chiang YT. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther. 2001; 23: 45-61.
4. Barilla D, Prasad P, Hubert M, Gumbhir-Shah K. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL. Biopharm Drug Dispos. 2004; 25: 51-59.
5. Bruckert E, Lievre M, Giral P Crepaldi G, Masana L, Vrolix M, Leitersdorf E, Dejager S. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol. 2003; 12: 225-231.
6. Faix D, Neese R, Kletke C, Wolden S, Cesar D, Coutlangus M, Shackleton CH, Hellerstein MK. Quantification of menstrual and diurnal periodicities in rates of cholesterol and fat synthesis in humans. J Lipid Res. 1993; 34: 2063-2075.
7. Harwood HJ, Bridge DM, Stacpoole PW. In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: studies in normal subjects. J Clin Invest. 1987; 79: 1125-1132.
8. Hiramatsu M, Hayashi A, Hidaka H, Ueshima H, Konno T. Enzyme immunoassay of urinary mevalonic acid and its clinical application. Clin Chem. 1998; 44: 2152-2157.
9. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoft N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fouler G, März W, Drexler H. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005; 111: 2356-2363.
10. Li PK, Mak TW, Wang AY, Lee YT, Leung CB, Lai SF Lam CW, Lai KN. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther. 1995; 33: 246-248.
11. Lindahl A, Sandstrom R, Ungell AL, Abrahamsson B, Knutson TW, Knutson L, Lennernas H. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther. 1996; 60: 493-503.
12. Lindenthal B, Simatupang A, Dotti MT, Federico A, Lütjohann D, von Bergmann K. Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. J Lipid Res. 1996; 37: 2193-2201.
13. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002; 54: 472-477.
14. Nozaki S, Nakagawa T, Nakata A, Yamashita S, Kameda-Takemura K, Nakamura T, Keno Y, Tokunaga K, Matsuzawa Y. Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration. Eur J Clin Pharm. 1996; 49: 361-364.
15. Olsson AG, Pauciullo P, Soska V, Luley C, Pieters RE, Broda G, Palacios B, Fluvastatin study group. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. Clin Ther. 2001; 23: 177-192.
16. Pappu AS, Illingworth DR, Bacon S. Reduction in plasma low-densitiy lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia. Metabolism. 1989; 38: 542-549.
17. Parker TS, McNamara DJ, Brown CD, Kolb R, Ahrens EH Jr. Alberts AW, Tobert J, Chen J, De Schepper PJ. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest. 1984; 74: 795-804.
18. Pfohl M, Naoumova RP, Kim KD, Thompson GR. Use of cholesterol precursors to assess changes in cholesterol synthesis under non-steady-state conditions. Eur J Clin Invest. 1998; 28: 491-496.
19. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, Kotze MJ, Heinonen TM, Black DM. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atheroscler. 2000; 150: 421-428.
20. Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I, Einarsson K, Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990; 323: 224-228.
21. Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol. 2001; 37: 502-511.
22. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb Vasc Biol. 1991; 11: 816-826.
23. Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. Int J Clin Pharmacol Ther. 1995; 33: 420-426.
24. Triscari J, Rossi L, Pan HY. Chronokinetics of pravastatin administered in the PM compared with AM dosing. Am J Ther. 1995; 2: 265-268.
25. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol. 1992; 32: 630-638.
26. Tse FL, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci. 1993; 82: 942-947.
27. Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ. 2003; 327: 788.